Details

Autor(en) / Beteiligte

• Pfützner, Andreas
• Schöndorf, Thomas
• Seidel, Daniela
• Winkler, Karl
• Matthaei, Stephan
• Hamann, Andreas
• Forst, Thomas

Titel

Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride

Ist Teil von

• Metabolism, clinical and experimental, 2006, Vol.55 (1), p.20-25

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• Addition of rosiglitazone to sulfonylurea has been shown to improve glycemic control in patients with type 2 diabetes previously treated with sulfonylurea monotherapy alone. This investigation was performed to assess the specific impact of rosiglitazone on insulin resistance, beta-cell function, cardiovascular risk markers, and adiponectin secretion in this treatment concept. One hundred two patients from a double-blind, 3-arm comparator trial (group 0, glimepiride + placebo, n = 30; group 4, glimepiride + 4 mg rosiglitazone, n = 31; group 8, glimepiride + 8 mg rosiglitazone, n = 41; 48 women, 54 men; age [mean ± SD], 62.8 ± 9.1 years; body mass index, 28.7 ± 4.5 kg/m 2; diabetes duration, 6.4 ± 4.8 years; HbA 1c, 8.1% ± 1.5%) were analyzed after 0 and 16 weeks of treatment. Observation parameters were HbA 1c, glucose, homeostasis model assessment for insulin resistance score, insulin, intact proinsulin, and adiponectin. Insulin resistance was defined by elevated intact proinsulin values or homeostasis model assessment for insulin resistance score of more than 2. All parameters were comparable in the 3 groups at baseline. Substantial and significant dose-dependent improvements were observed after addition of rosiglitazone for fasting glucose (group 0, −9 ± 48 mg/dL; group 4, −38 ± 47 mg/dL; group 8, −46 ± 53 mg/dL), HbA 1c (−0.1% ± 0.7%, −1.1% ± 1.2%, −1.3% ± 1.2%), insulin (1.4 ± 6.2, −1.2 ± 5.3, −3.7 ± 9.9 μU/mL), intact proinsulin (1.6 ± 7.1, −2.0 ± 4.6, −3.1 ± 6.1 pmol/L), and high-sensitivity C-reactive protein (0.2 ± 2.6, −1.7 ± 3.5, −2.1 ± 3.5 mg/L). After adjustment for changes in body weight, significant increases in adiponectin were detected with rosiglitazone, whereas glimepiride alone did not induce a comparable effect (−0.5 ± 5.8, 8.8 ± 22.9, 14.3 ± 19.9 mg/L). The number of insulin-resistant patients decreased in both rosiglitazone treatment groups, whereas no change was seen with glimepiride alone. Next to the reported effects on glucose control, rosiglitazone provided an additional beneficial effect on insulin resistance, beta-cell function, and cardiovascular risk markers. In conclusion, our short-term investigation of rosiglitazone action provides further experimental support for the rationale of combining rosiglitazone with sulfonylurea drugs in patients with type 2 diabetes.